Success Metrics

Clinical Success Rate

100.0%

Based on 3 completed trials

Completion Rate

100%(3/3)

Active Trials

4(50%)

Results Posted

67%(2 trials)

Phase Distribution

Ph phase_4

13%

Ph phase_1

13%

Ph phase_2

13%

Ph phase_3

38%

Phase Distribution

Early Stage

Mid Stage

Late Stage

Phase Distribution6 total trials

Phase 1Safety & dosage

1(16.7%)

Phase 2Efficacy & side effects

1(16.7%)

Phase 3Large-scale testing

3(50.0%)

Phase 4Post-market surveillance

1(16.7%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

100.0%

3 of 3 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

trials recruiting

Total Trials

all time

Status Distribution

Active(4)

Completed(3)

Other(1)

Detailed Status

Completed3

Recruiting3

unknown1

Active, not recruiting1

Development Timeline

Analytics

Development Status

Total Trials

Active

Success Rate

100.0%

Most Advanced

Phase 4

Trials by Phase

Phase 11 (16.7%)

Phase 21 (16.7%)

Phase 33 (50.0%)

Phase 41 (16.7%)

Trials by Status

completed338%

unknown113%

active_not_recruiting113%

recruiting338%

Recent Activity

4 active trials

Showing 5 of 8

recruiting

A Study to Learn More About the Long-Term Safety of Tofersen (Qalsody) in Participants With Superoxide Dismutase 1 (SOD-1) Amyotrophic Lateral Sclerosis (ALS)

NCT07259980

active_not_recruitingphase_3

A Study of BIIB067 (Tofersen) Initiated in Clinically Presymptomatic Adults With a Confirmed Superoxide Dismutase 1 Mutation

NCT04856982

recruitingphase_2

Tofersen in Non-SOD1 ALS

NCT07294144

recruitingphase_4

A Study to Learn More About the Long-Term Safety of Tofersen (Qalsody) in Chinese Participants With SOD-1 Amyotrophic Lateral Sclerosis (ALS)

NCT07223723

completedphase_3

Long-Term Evaluation of BIIB067 (Tofersen)

NCT03070119

View all 8 trials

Clinical Trials (8)

Showing 8 of 8 trials

NCT07259980

A Study to Learn More About the Long-Term Safety of Tofersen (Qalsody) in Participants With Superoxide Dismutase 1 (SOD-1) Amyotrophic Lateral Sclerosis (ALS)

Recruiting

NCT04856982Phase 3

A Study of BIIB067 (Tofersen) Initiated in Clinically Presymptomatic Adults With a Confirmed Superoxide Dismutase 1 Mutation

Active Not Recruiting

NCT07294144Phase 2

Tofersen in Non-SOD1 ALS

Recruiting

NCT07223723Phase 4

A Study to Learn More About the Long-Term Safety of Tofersen (Qalsody) in Chinese Participants With SOD-1 Amyotrophic Lateral Sclerosis (ALS)

Recruiting

NCT03070119Phase 3

Long-Term Evaluation of BIIB067 (Tofersen)

Completed

NCT04972487

Expanded Access Program for Tofersen in Participants With Superoxide Dismutase 1-Amyotropic Lateral Sclerosis

Unknown

NCT02623699Phase 3

An Efficacy, Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Study of BIIB067 (Tofersen) in Adults With Inherited Amyotrophic Lateral Sclerosis (ALS)

Completed

NCT03764488Phase 1

A Study to Evaluate Safety, Tolerability, and Distribution of a Microdose of Radiolabeled BIIB067 (99mTc-MAG3-BIIB067) Co-administered With BIIB067 (Tofersen) to Healthy Adults

Completed

All 8 trials loaded

Drug Details

Intervention Type: DRUG
Total Trials: 8